This company has been acquired
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
FRLN Overzicht aandelen
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies.
| Sneeuwvlok Score | |
|---|---|
| Waardering | 2/6 |
| Toekomstige groei | 5/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 4/6 |
| Dividenden | 0/6 |
Freeline Therapeutics Holdings plc Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$6.48 |
| 52 Week Hoogtepunt | US$8.70 |
| 52 Week Laag | US$2.11 |
| Bèta | 0.66 |
| 11 maand verandering | 1.25% |
| 3 maanden verandering | 1.73% |
| 1 Jaar Verandering | -21.67% |
| 33 jaar verandering | -97.13% |
| 5 jaar verandering | n/a |
| Verandering sinds IPO | -97.60% |
Recent nieuws en updates
Recent updates
Calculating The Intrinsic Value Of Freeline Therapeutics Holdings plc (NASDAQ:FRLN)
Jul 13
Here's Why Freeline Therapeutics Holdings (NASDAQ:FRLN) Must Use Its Cash Wisely
Apr 11Here's Why Freeline Therapeutics Holdings (NASDAQ:FRLN) Must Use Its Cash Wisely
Dec 20We're Keeping An Eye On Freeline Therapeutics Holdings' (NASDAQ:FRLN) Cash Burn Rate
Aug 30Freeline gains as NEJM publishes long-term data for hemophilia therapy
Jul 21Is Freeline Therapeutics Holdings (NASDAQ:FRLN) In A Good Position To Invest In Growth?
May 05Will Freeline Therapeutics Holdings (NASDAQ:FRLN) Spend Its Cash Wisely?
Jan 13Companies Like Freeline Therapeutics Holdings (NASDAQ:FRLN) Could Be Quite Risky
Sep 30Here's Why We're Watching Freeline Therapeutics Holdings' (NASDAQ:FRLN) Cash Burn Situation
Jun 03What Kind Of Shareholders Hold The Majority In Freeline Therapeutics Holdings plc's (NASDAQ:FRLN) Shares?
Feb 18
Rendement voor aandeelhouders
| FRLN | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | -0.2% | -0.5% | 0.4% |
| 1Y | -21.7% | 18.3% | 32.6% |
Rendement versus industrie: FRLN underperformed the US Biotechs industry which returned 4.4% over the past year.
Rendement versus markt: FRLN underperformed the US Market which returned 20.5% over the past year.
Prijsvolatiliteit
| FRLN volatility | |
|---|---|
| FRLN Average Weekly Movement | 3.5% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiele aandelenkoers: FRLN's share price has been volatile over the past 3 months.
Volatiliteit in de loop van de tijd: FRLN's weekly volatility has decreased from 17% to 4% over the past year.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2015 | 152 | Michael Parini | www.freeline.life |
Freeline Therapeutics Holdings plc Samenvatting
| FRLN fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$28.25m |
| Inkomsten(TTM) | -US$49.93m |
| Inkomsten(TTM) | US$622.00k |
45.4x
P/S-verhouding-0.6x
Koers/WinstverhoudingIs FRLN overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| FRLN resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$622.00k |
| Kosten van inkomsten | US$0 |
| Brutowinst | US$622.00k |
| Overige uitgaven | US$50.55m |
| Inkomsten | -US$49.93m |
Laatst gerapporteerde inkomsten
Sep 30, 2023
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -11.45 |
| Brutomarge | 100.00% |
| Nettowinstmarge | -8,027.65% |
| Schuld/Eigen Vermogen Verhouding | 0% |
Hoe presteerde FRLN op de lange termijn?
Bekijk historische prestaties en vergelijking